Virginia G. Piper Biodesign Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona.
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2475-2485. doi: 10.1158/1055-9965.EPI-20-0331. Epub 2020 Sep 29.
In spite of the progress made in treatment and early diagnosis, breast cancer remains a major public health issue worldwide. Although modern image-based screening modalities have significantly improved early diagnosis, around 15% to 20% of breast cancers still go undetected. In underdeveloped countries, lack of resources and cost concerns prevent implementing mammography for routine screening. Noninvasive, low-cost, blood-based markers for early breast cancer diagnosis would be an invaluable alternative that would complement mammography screening. Tumor-specific autoantibodies are excellent biosensors that could be exploited to monitor disease-specific changes years before disease onset. Although clinically informative autoantibody markers for early breast cancer screening have yet to emerge, progress has been made in the development of tools to discover and validate promising autoantibody signatures. This review focuses on the current progress toward the development of autoantibody-based early screening markers for breast cancer.
尽管在治疗和早期诊断方面取得了进展，但乳腺癌仍然是全球范围内的一个主要公共卫生问题。尽管现代基于影像的筛查方式显著提高了早期诊断水平，但仍有约 15%至 20%的乳腺癌未被发现。在欠发达国家，资源匮乏和成本问题使得常规筛查无法实施乳房 X 光检查。用于早期乳腺癌诊断的无创、低成本、基于血液的标志物将是一种非常有价值的替代方法，可以补充乳房 X 光筛查。肿瘤特异性自身抗体是出色的生物传感器，可用于在疾病发作前数年监测疾病特异性变化。尽管用于早期乳腺癌筛查的临床信息自身抗体标志物尚未出现，但在开发用于发现和验证有前途的自身抗体特征的工具方面已经取得了进展。本文重点介绍了基于自身抗体的乳腺癌早期筛查标志物的开发的最新进展。
